PD-L1 genetic overexpression or pharmacological restoration in hematopoietic stem and progenitor cells reverses autoimmune diabetes-Reference-Cited by-同舟云学术

PD-L1 genetic overexpression or pharmacological restoration in hematopoietic stem and progenitor cells reverses autoimmune diabetes

Published:2017-11-15 Issue:416 Volume:9 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Ben Nasr Moufida¹²^ORCID,Tezza Sara¹^ORCID,D’Addio Francesca¹²^ORCID,Mameli Chiara³,Usuelli Vera¹²,Maestroni Anna²,Corradi Domenico⁴,Belletti Silvana⁴,Albarello Luca⁵,Becchi Gabriella⁴,Fadini Gian Paolo⁶^ORCID,Schuetz Christian⁷^ORCID,Markmann James⁷,Wasserfall Clive⁸,Zon Leonard⁹^ORCID,Zuccotti Gian Vincenzo²³,Fiorina Paolo¹²¹⁰^ORCID

Affiliation:

1. Nephrology Division, Boston Children’s Hospital, Harvard Medical School, Boston, MA 02115, USA.

2. International Center for T1D, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, “L. Sacco” Department of Biomedical and Clinical Sciences, University of Milan, Milan 20157, Italy.

3. Department of Pediatrics, Buzzi Children’s Hospital, Milan 20154, Italy.

4. Pathology Unit, University of Parma, Parma 43126, Italy.

5. Pathology Unit, Ospedale San Raffaele, Milan 20132, Italy.

6. Department of Medicine, University of Padua, Padua 35100, Italy.

7. Department of Surgery, Massachusetts General Hospital, Boston, MA 02114, USA.

8. Department of Pathology, University of Florida, Gainesville, FL 32611, USA.

9. Division of Hematology/Oncology, Boston Children’s Hospital, Harvard Medical School, Boston, MA 02115, USA.

10. Department of Endocrinology, ASST Fatebenefratelli-Sacco, Milan 20121, Italy.

Abstract

Restoration of a PD-L1 defect in HSPCs reverses diabetes in NOD mice and thus may represent a potential cure for T1D.

Funder

Fate therapeutics

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference27 articles.

1. Genetics, pathogenesis and clinical interventions in type 1 diabetes

2. Immunomodulatory Function of Bone Marrow-Derived Mesenchymal Stem Cells in Experimental Autoimmune Type 1 Diabetes

3. Targeting CD22 Reprograms B-Cells and Reverses Autoimmune Diabetes

4. A Novel Clinically Relevant Strategy to Abrogate Autoimmunity and Regulate Alloimmunity in NOD Mice

5. The rise, fall, and resurgence of immunotherapy in type 1 diabetes

Cited by 97 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Regulatory T cell-based therapy in type 1 diabetes: Latest breakthroughs and evidence;International Immunopharmacology;2024-10

2. Cell–drug conjugates;Nature Biomedical Engineering;2024-07-01

3. Bioengineered Artificial Extracellular Vesicles Presenting PD-L1 and Gal-9 Ameliorate New-Onset Type 1 Diabetes;Diabetes;2024-05-21

4. Type 1 diabetes: A new vision of the disease based on endotypes;Diabetes/Metabolism Research and Reviews;2024-02

5. High glucose-induced injury in human umbilical vein endothelial cells is alleviated by vitamin D supplementation through downregulation of TIPE1;Diabetology & Metabolic Syndrome;2024-01-13